Biovest Ends Therapeutic Cancer Vaccine Trial Early On Positive DMC Signal
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm seeks “accelerated or conditional” approval path from FDA.
You may also be interested in...
SinuNase Effective For Severe, Chronic Sinusitis After All
Results make a compelling argument to partnering candidates, Accentia tells “The Pink Sheet” DAILY.
SinuNase Effective For Severe, Chronic Sinusitis After All
Results make a compelling argument to partnering candidates, Accentia tells “The Pink Sheet” DAILY.
Antigenics’ Oncophage Approved In Russia, First Therapeutic Cancer Vaccine To Enter Marketplace
The biologic will launch this summer at a price in the lower range of $50,000-$100,000/patient/year, the typical cost of new cancer drugs in Russia, firm tells “The Pink Sheet” DAILY.